www.pharmaceutical-tech.com View this email online »
Hospitals Management

June 2013, e-Newsletter
Advertise   |    Archives

Articles

Nanonization of Active Pharmaceutical Ingredients

The comminution or desagglomeration of Active Pharmaceutical Ingredients (API) is called micronization. Nanonization is a term for reducing particle size to the nanometer range and brings about several advantages. It further increases the surface area of API’s which could result in enhanced solubility and drug bioavailability. Reducing the particle size of an API possessing poor solubility characteristics can lead to higher specific surface area, thereby increasing bioavailability and dissolution rate. Due to the increased bioavailability a lower amount of API is required which in turn leads to a more cost-efficient product with less risks and side effects for the patient.

Global Awards
Featured Products
Lab Products & Services
Lab Products & Services
Sartorius products accelerate scientific progress, while enabling dependable, efficient analyses to be performed in labs.
know more»
Nonsterile Filling
Nonsterile Filling
Be it compact monoblock machines or complete packaging lines: The machine program includes individual solutions for cGMP-conforming production as well as a complete program for all dosage forms,...
know more»
Plasma Technology
Plasma Technology
Deposition of the active content of a drug formulation on can surfaces is a problem with some MDI products. This ultimately leads to a reduction in the drug content in the formulation, resulting in the patient receiving less than the prescribed dose.
know more»
CPHI India
Industry Updates
News
KLOX Technologies to Present Clinical Trial Results for its Innovative AC-1 BioPhotonic Platform in Greece and Canada
MONTREAL, June 28, 2013
KLOX Technologies Inc. announced today that it will be presenting the clinically-significant results of its registration trial for its AC-1 BioPhotonic system, an innovative and effective treatment for moderate to severe...
Press Release
Pfizer Declares 24-Cent Third-Quarter 2013 Dividend
NEW YORK, June 27, 2013
The board of directors of Pfizer Inc. today declared a 24-cent third-quarter 2013 dividend on the company’s common stock, payable September 4, 2013, to shareholders of record at the close of business on August 2, 2013. The third-quarter 2013 cash dividend will be the 299th consecutive quarterly dividend paid by Pfizer.
Events and Exhibition
Pharma Trials World Korea 2013
Jul 8 2013 - Jul 11 2013
Korea,South Korea
Republic of Korea
Terrapinn Pte Ltd
Subscribe Unsubscribe Advertise Archives
Copyright © 2013. All rights reserved